| Name | Title | Contact Details |
|---|
RadiaShield is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Dionex Corporation (Dionex) designs, manufactures, markets, and services analytical instrumentation, related accessories, and chemicals. Its products are used to analyze chemical substances in the environment and in a range of industrial and scientific
DermaMed Solutions helps spa owners, dermatologists, plastic surgeons and other skin care and medical professionals expand their practices to include additional services. Entrepreneur Roger Parkin founded our company in 1998. Inspiration came when an aesthetician suggested he develop a quieter microdermabrasion machine. The result was MegaPeel®. Besides being quieter than similar devices, our microdermabrasion system was smaller, was easier to use and reduced troublesome vibrations.
Xenter, Inc. is a privately held company headquartered in Salt Lake City, Utah, that is focused on developing new wireless medical device technologies, innovative digital health tools that will enable individual patients to own and manage their health information, and novel therapeutic drugs utilizing Physical Intelligence™ and patient-supplied data. Xenter has assembled a team of medical scientists, chemical engineers, medical device engineers, researchers, data scientists, and some of the world`s most accomplished entrepreneurs and industry veterans to solve some of the largest challenges in healthcare, medicine and engineering.
At T2 Biosystems, we are united in our mission: to improve patient outcomes, lower mortality rates and reduce the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. By leveraging the power of our innovative and proprietary T2 Magnetic Resonance (T2MR) platform, T2 Biosystems’ diagnostics are designed to provide faster, easier and more accurate results than traditional methodologies. T2 Biosystems is currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. Our T2Candida Panel tackles sepsis and is the first FDA-cleared diagnostic panel requiring no blood culture – delivering more accurate results in hours versus days. Other ongoing development efforts include bacterial and hemostasis panels, as well as a Lyme disease partnership with Canon Life Sciences. Over 100 studies published in peer-reviewed journals have featured T2MR technology in a breadth of applications, including the direct detection and measurement of targets in various sample types, such as whole blood, plasma, serum, saliva, sputum and urine. With limits of detection as low as 1 CFU/mL, we believe T2MR technology will drive the next generation of diagnostics.